Genmab
genmab.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
5
RA Capital Management, HongShan
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 2026
Formerly Genmab A/S (profoundbio.com)
Sep 29, 2025
Acquisition Genmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into Revenue · seekingalpha.com
Backed byfrom the funds' portfolios and accelerator catalogs
RA Capital Management 
LAV 
Nextech Invest 
Sofinnova Investments Overview
Transforming lives with pioneering antibody science. Previous.
News
Genmab stock reflects higher 2026 revenue guidance
Genmab stock trades at DKK 2,282.00 on September 28, 2026, after a 0.22 percent rise. H1 revenue reached USD 2.051 billion, up 25 percent year over year.
Read more
Report
Genmab stock last trades at DKK 2,282.00 on September 28, 2026
Genmab last traded at DKK 2,282.00 on Nasdaq Copenhagen on September 28, 2026, up 0.22 percent. The company also disclosed new employee equity awards.
Read more
Report
Genmab Grants New Employee Restricted Stock Units and Warrants
Detailed price information for Genmab A/S ADR (GMAB-Q) from The Globe and Mail including charting and trades.
Read more
Report
Wells Fargo Gives a Buy Rating to Genmab (GMAB)
Detailed price information for Genmab A/S ADR (GMAB-Q) from The Globe and Mail including charting and trades.
Read more
Report
From antibody science to patient impact: Genmab's next phase
As the oncology landscape continues to evolve, companies are increasingly evaluated on their ability to translate scientific expertise into sustained
Read more
Report
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Genmab A/S (Nasdaq: GMAB) (
Read more
Report
Why Genmab Stock Was Marching Higher Today
The company's latest asset purchase seems to be impressing analysts.
Read more
Report
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Genmab A/S (Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. F...
Read more
Report